Gregory L. Beatty
Oncology
3400 Civic Center Boulevard
West Pavilion, 2nd Floor
Philadelphia, PA 19104
West Pavilion, 2nd Floor
Philadelphia, PA 19104
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 72 publications
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in in vivo and ex vivo models.
Journal: Oncoimmunology
Published: December 29, 2025
Spatial Biology and Organoid Technologies Reveal a Potential Therapy-Resistant Cancer Stem Cell Population in Pancreatic Ductal Adenocarcinoma.
Journal: bioRxiv : the preprint server for biology
Published: July 15, 2025
TLR2 signaling regulates T cell exclusion in pancreatic ductal adenocarcinoma.
Journal: JCI insight
Published: May 05, 2025
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1.
Journal: Cell reports. Medicine
Published: February 21, 2025
Facts and Hopes of CD40 Agonists in Cancer Immunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.
Journal: Science translational medicine
Published: October 23, 2024
Manufacturing of CRISPR-edited primary mouse CAR T cells for cancer immunotherapy.
Journal: Nature protocols
Published: September 06, 2024
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer.
Journal: Carcinogenesis
Published: August 07, 2024
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models.
Journal: Cancer cell
Published: April 26, 2024
Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1.
Journal: Science immunology
Published: November 17, 2023
Last Updated: 09/26/2026